Amneal Pharmaceuticals, Inc.
No SEC Form 4 filings for $AMRX in the last 30 days.
See all $AMRX insider activity →Amneal Pharmaceuticals (AMRX) amended its term loan credit agreement to add a $350 million incremental term loan, according to an Aug. 10, 2026 SEC filing. Bank of America provided the loan, with JPMorgan Chase as administrative agent. Proceeds will fund the cash portion of Amneal’s Kashiv acquisition and related liquidity needs.
Amneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 ef20079825_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “ Amendment ”), is entered into as of August 10
Amneal Pharmaceuticals (NASDAQ: AMRX) said it completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The company expects access to a market with over $300 billion in projected biologics loss of exclusivity over the next decade and plans to accelerate biosimilar launches. Advisors included Goldman Sachs and J.P. Morgan.
Over the past 7 days, alphai's AI scored 3 news stories mentioning AMRX (Amneal Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent AMRX coverage spans earnings, mergers & acquisitions and corporate actions.
The incremental debt financing supports deal funding and may affect near-term leverage and interest expense expectations.
The filing signals a completed asset transaction and related governance/registration updates, which can affect capital structure, ownership rights, and deal-related obligations.
Deal completion should improve Amneal’s biosimilars execution capability, but near-term earnings impact is uncertain due to integration and pipeline execution risk.
The 8-K discloses a debt refinancing and credit agreement amendment, which can affect near-term liquidity, leverage optics, and interest expense expectations.
Guidance raise and acquisition benefit framing are near-term valuation drivers, while Gujarat flood and late biosimilar launch timing add execution risk.
alphai scores every news story that mentions AMRX with an AI model for sentiment and relevance, and aggregates insider trades from Amneal Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amneal Pharmaceuticals (AMRX) amended its term loan credit agreement to add a $350 million incremental term loan, according to an Aug. 10, 2026 SEC filing. Bank of America provided the loan, with JPMorgan Chase as administrative agent. Proceeds will fund the cash portion of Amneal’s Kashiv acquisition and related liquidity needs.
1 min readAmneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 ef20079825_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “ Amendment ”), is entered into as of August 10
2 min readAmneal Pharmaceuticals (NASDAQ: AMRX) said it completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform. The company expects access to a market with over $300 billion in projected biologics loss of exclusivity over the next decade and plans to accelerate biosimilar launches. Advisors included Goldman Sachs and J.P. Morgan.
4 min readAmneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 a20260803_repricingpacka.htm EX-10.1 a20260803_repricingpacka Execution Version 1 4896-6230-8791.1 AMENDMENT NO. 3 TO TERM LOAN CREDIT AGREEMENT AMENDMENT NO. 3 TO TERM LOAN CREDIT AGREEMENT, dated as of August 3, 2026 (this “Amendment”), to the Term Loan Credit Agreeme
4 min readAmneal Pharmaceuticals reported its Q2 2026 earnings call, citing a shift to complex, high-value medicines. Management said revised FDA guidance boosted demand for transdermal patches and drove a capacity tripling. It raised 2026 revenue guidance by $50 million to $3.1B-$3.2B, increased CapEx to $150M, and expects Kashiv acquisition benefits of $400M-$500M. Flood impacts were estimated at $20M negative.
7 min readAmneal (AMRX) said Q2 results reflected execution in complex generics, specialty brands, and manufacturing efficiency. It cited growth in transdermal women’s health patches after revised FDA guidance and strong uptake of CREXONT and BREKIYA. Management expects Kashiv to expand biosimilars and target six commercial launches next year, while also increasing capacity for patches and injectables.
7 min readAmneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001723128 0001723128 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2026 A
4 min readThursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeo Co-Founder and Co-Chief Executive Officer - Chirag Patel Co-Founder and Co-Chief Executive Officer - Chintu Patel Chief Financial Officer - Anastasios Konidaris Specialty - Joe Renda Chief Legal Officer - Jason Daly TAKEAWAYS Revenue -- $796 million, up 10% year over year driven by broad-based momentum across all three business segments.
6 min readAmneal Pharmaceuticals (AMRX) reported Q2 revenue of $796.2M, up 9.9% year over year, beating the Zacks Consensus estimate of $767.81M by 3.7%. EPS was $0.30 versus $0.25 a year earlier, and above the $0.24 consensus by 25%. Segment net revenue also varied versus estimates.
3 min readAmneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results. Revenue rose 9.9% year on year to $796.2 million and exceeded expectations by 3.6%. Full-year revenue guidance was $3.15 billion at the midpoint, 1.1% above estimates. Non-GAAP EPS was $0.30, 30.3% above consensus, and the stock rose 15.9% to $22.13.
4 min read
